Catherine D. Angwin

Patient stratification for determining optimal second and third line therapy for type 2 diabetes: the TriMaster study

A. Farmer, B. Shields, A. Hattersley, 2022, Nature Medicine.

Patient preference for second and third line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study

B. Shields, A. Hattersley, R. Holman, 2022, Nature Medicine.